Codis to Acquire Catalent's Facility in Nottingham, UK

Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering solutions, announced the acquisition of Catalent Pharma Solutions' facility in Nottingham, UK. The agreement is set to be finalized in Q3 of 2026, subject to customary closing conditions. This acquisition will add oral solid dose (OSD) development and small-scale manufacturing capabilities, positioning Codis as Europe's leading single partner for integrated spray dry solutions.

The Nottingham site will bring a highly experienced team and deep scientific expertise in formulation development and clinical supply. The acquisition is expected to strategically complement Codis' large scale commercial spray drying facility in Haverhill, UK, which is currently undergoing significant expansion. Nicolas Fortin, CEO of Codis, highlighted the advantages of the acquisition, stating that it will establish Codis as a leading European provider of comprehensive spray dry solutions by integrating scientific expertise and manufacturing capabilities within a single organization.

The move also aims to address the challenge of poor solubility in small-molecule drug candidates through spray-dried dispersions, while minimizing the risks associated with the transfer from formulation to commercial-scale manufacturing. Codis is a global CDMO specializing in commercial spray drying, amorphous solid dispersions, particle engineering, and finished dose manufacturing for the pharmaceutical, consumer health, nutraceutical, and OTC sectors.

The company operates cGMP facilities in St. Louis, Missouri, Seymour, Indiana, and Haverhill, UK. For media inquiries, please contact Gillian Lott and Miles Fisher-Pollard at Codis.